Sintx Revenue Plummets 66% Amid Widening Losses, Shifts to Biomedical Focus

TL;DR

**SINT is burning cash and its revenue is in freefall; the biomedical pivot is a Hail Mary pass, but don't bet on it without a clear path to profitability.**

AI Summary

Sintx Technologies, Inc. (SINT) reported a significant decline in total revenue for the six months ended June 30, 2025, falling to $520,000 from $1,546,000 in the prior year, a 66.4% decrease. Product revenue specifically dropped from $687,000 to $391,000, and grant and contract revenue decreased from $859,000 to $129,000. The company's net loss widened to $4.61 million for the six months ended June 30, 2025, compared to a net loss of $3.09 million for the same period in 2024. Despite the increased net loss, cash used in operating activities improved, decreasing to $3.71 million from $4.95 million year-over-year. SINTX raised $4.38 million from the issuance of common stock and prefunded warrants, net of cash fees, during the first half of 2025. The company's strategic outlook is now solely focused on biomedical applications, particularly silicon nitride for musculoskeletal and antipathogenic uses, and it recently submitted a 510(k) premarket notification to the FDA for novel silicon nitride osteotomy wedges in July 2025. SINTX continues to face liquidity challenges, with an accumulated deficit of $286 million as of June 30, 2025, and acknowledges the need for substantial future capital.

Why It Matters

Sintx Technologies' sharp revenue decline and widening net loss signal significant operational challenges, raising red flags for investors regarding its financial viability and ability to scale. The strategic pivot to an exclusive biomedical focus, highlighted by the FDA 510(k) submission for osteotomy wedges, is a high-stakes move to carve out a niche in the competitive medical device market. Success in this area could attract new investment and partnerships, but failure would exacerbate its precarious financial position. Employees face uncertainty given the company's ongoing losses and capital needs, while customers in its former industrial segments will need to seek alternative suppliers. The broader market will watch if SINTX can successfully transition and compete against established biomaterials companies.

Risk Assessment

Risk Level: high — Sintx Technologies reported an accumulated deficit of $286 million as of June 30, 2025, and a net loss of $4.61 million for the six months ended June 30, 2025. The company explicitly states its continuation as a going concern is dependent on increasing sales, decreasing expenses, and raising additional funding, which is not guaranteed and may be dilutive to current stockholders.

Analyst Insight

Investors should exercise extreme caution and consider divesting if they hold SINT shares, given the significant revenue decline, widening losses, and explicit going concern risk. Potential investors should avoid SINT until there is clear evidence of successful commercialization of its biomedical products, substantial revenue growth, and a solidified capital structure.

Financial Highlights

debt To Equity

N/A

revenue

$520,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$4.61 million

eps

N/A

gross Margin

N/A

cash Position

$4,320

revenue Growth

-66.4%

Revenue Breakdown

Key Numbers

• $520,000 — Total Revenue (for six months ended June 30, 2025, down 66.4% from $1,546,000 in 2024)
• $4.61 million — Net Loss (for six months ended June 30, 2025, widened from $3.09 million in 2024)
• $3.71 million — Cash Used in Operating Activities (for six months ended June 30, 2025, an improvement from $4.95 million in 2024)
• $286 million — Accumulated Deficit (as of June 30, 2025, up from $281.7 million as of December 31, 2024)
• $4.38 million — Proceeds from Equity Issuance (from common stock and prefunded warrants, net of cash fees, for six months ended June 30, 2025)
• 2,758,865 — Shares of Common Stock Outstanding (as of August 8, 2025)
• $4,320 — Cash and Cash Equivalents (as of June 30, 2025, up from $3,598 as of December 31, 2024)
• $100 — Product Revenue (for three months ended June 30, 2025, down from $378 in 2024)
• $51 — Grant and Contract Revenue (for three months ended June 30, 2025, down from $481 in 2024)

Key Players & Entities

• Sintx Technologies, Inc. (company) — registrant
• SINTX Armor, Inc. (company) — wholly-owned subsidiary
• SINTX Agribiotech, Inc. (company) — wholly-owned subsidiary
• Technology Assessment and Transfer, Inc. (company) — wholly-owned subsidiary until February 19, 2025
• U.S. Food and Drug Administration (FDA) (regulator) — regulatory body for medical devices
• NASDAQ Capital Market (company) — stock exchange
• Salt Lake City, Utah (location) — location of manufacturing facilities
• Chief Executive Officer (person) — Chief Operating Decision Maker (CODM)
• Bloomberg (company) — financial news organization

FAQ

Risk Factors

• Liquidity and Need for Capital [high — financial]: SINTX faces ongoing liquidity challenges, evidenced by an accumulated deficit of $286 million as of June 30, 2025. The company explicitly acknowledges the need for substantial future capital to continue operations, indicating a high degree of financial risk.
• FDA Approval Process [medium — regulatory]: The company's strategic focus on biomedical applications, including the recent submission of a 510(k) for osteotomy wedges, exposes it to the lengthy and uncertain FDA approval process. Delays or rejections could significantly impact revenue and market entry.
• Revenue Decline and Operational Scale [high — operational]: Total revenue for the six months ended June 30, 2025, plummeted by 66.4% to $520,000 from $1,546,000 in the prior year. This drastic decline suggests significant operational challenges or a lack of market traction for current offerings.
• Widening Net Loss [high — financial]: The net loss for the six months ended June 30, 2025, increased to $4.61 million from $3.09 million in the same period last year. This widening loss, despite revenue declines, points to potential cost control issues or increased operating expenses relative to revenue.

Industry Context

SINTX operates in the highly competitive medical device and advanced materials sectors. The biomedical segment, particularly for orthopedic and antipathogenic applications, is driven by innovation and regulatory hurdles. Companies like SINTX must navigate stringent FDA approval processes and demonstrate clear clinical benefits and cost-effectiveness against established players.

Regulatory Implications

The company's pivot to biomedical applications means increased reliance on FDA approvals. The 510(k) submission for osteotomy wedges is a critical step, but the outcome and timeline are uncertain. Failure to gain approval or significant delays could derail the company's strategic direction and financial recovery.

What Investors Should Do

1. Monitor FDA 510(k) decision timeline and outcome.
2. Assess future capital raise needs and dilution.
3. Evaluate the sustainability of the reduced operating cash burn.

Key Dates

• 2025-07-01: FDA 510(k) Submission — Marks a critical step in the regulatory approval process for SINTX's novel silicon nitride osteotomy wedges, a key product in their biomedical strategy.
• 2025-06-30: End of Second Quarter Reporting Period — Provides the latest financial snapshot, highlighting a significant revenue decline and widening net loss, alongside improved cash burn from operations.
• 2024-12-31: End of Fiscal Year 2024 — Represents the prior year's financial standing, showing a higher revenue base and a smaller accumulated deficit compared to the current period.

Glossary

510(k) premarket notification

A process by which manufacturers demonstrate to the FDA that their proposed medical device is safe and effective by showing it is substantially equivalent to a legally marketed device. (Crucial for SINTX's strategy to bring its biomedical products to market, as it's a prerequisite for FDA clearance.)

Osteotomy wedges

Surgical implants used to correct bone deformities or malalignments by creating a wedge-shaped gap or removal in the bone. (Represents a specific application of SINTX's silicon nitride technology in the musculoskeletal field, a core focus area.)

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates SINTX's long-standing history of unprofitability, with a substantial deficit of $286 million as of June 30, 2025.)

Prefunded warrants

A type of warrant that allows the holder to purchase shares of stock at a specified price, but the exercise price is typically nominal or zero, and the warrant is exercised immediately upon issuance. (SINTX used these in its recent equity issuance, indicating a method to raise capital while potentially offering immediate equity to investors.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, SINTX has experienced a dramatic 66.4% decline in total revenue, falling to $520,000. This revenue contraction has led to a widening net loss, increasing from $3.09 million to $4.61 million. Despite these negative trends, the company has managed to reduce its cash burn from operations, a positive sign in its efforts to conserve capital amidst significant financial challenges.

Filing Documents

• form10-q.htm (10-Q) — 896KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32.htm (EX-32) — 8KB
• 0001641172-25-024040.txt ( ) — 4884KB
• sint-20250630.xsd (EX-101.SCH) — 38KB
• sint-20250630_cal.xml (EX-101.CAL) — 62KB
• sint-20250630_def.xml (EX-101.DEF) — 160KB
• sint-20250630_lab.xml (EX-101.LAB) — 334KB
• sint-20250630_pre.xml (EX-101.PRE) — 258KB
• form10-q_htm.xml (XML) — 695KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 24

Controls and Procedures

Item 4. Controls and Procedures 24

Other Information

Part II. Other Information

Legal Proceedings

Item 1. Legal Proceedings 25

Risk Factors

Item 1A. Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 25

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 25

Other Information

Item 5. Other Information 25

Exhibits

Item 6. Exhibits 26

Signatures

Signatures 27 2 SINTX Technologies, Inc. Condensed Consolidated Balance Sheets - Unaudited (in thousands, except share and per share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 4,320 $ 3,598 Account and other receivables, net of allowance of $ 2.5 and $ 61.0 respectively 97 196 Prepaid expenses and other current assets 731 465 Inventories 355 502 Other current assets 45 10 Total current assets 5,548 4,771 Inventories, net 450 465 Property and equipment, net 499 922 Intangible assets, net 14 16 Operating lease right of use asset 2,613 3,159 Other long-term assets 71 80 Total assets $ 9,195 $ 9,413 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 183 $ 299 Accrued liabilities 585 986 Debt 109 32 Derivative liabilities 160 208 Current portion of operating lease liability 371 456 Other current liabilities 750 1 Total current liabilities 2,158 1,982 Operating lease liability, net of current portion 3,049 3,537 Total liabilities 5,207 5,519 Commitments and contingencies - - Stockholders' equity: Convertible preferred stock Series B, $ 0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 19 shares issued and outstanding as of June 30, 2025 and December 31, 2024. - - Convertible preferred stock Series C, $ 0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 50 shares issued and outstanding as of June 30, 2025 and December 31, 2024. - - Convertible preferred stock Series D, $ 0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 180 shares issued and outstanding as of June 30, 2025 and December 31, 2024. - - Convertible preferred stock, value - - Common stock, $ 0.01 par value, 250,000,000 shares authorized; 2,540,747 and 1,342,853 shares issued and 2,486,646 and 1,342

financial statements do not include any adjustments that might result from the outcome of these uncertainties

financial statements do not include any adjustments that might result from the outcome of these uncertainties. 9 Recent Accounting Pronouncements ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" on the topic of income taxes. The standard requires additional disclosure for income taxes. These requirements include: (i) requiring a public entity to disclose specific categories in the rate reconciliation; (ii) disclosure of additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate); (iii) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; (iv) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5% of total income taxes paid (net of refunds received); (v) annual disclosure of income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign; and (vi) annual disclosure of income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. For public entities, theguidance is effective for annual periods beginning after December 15, 2024. The Company will adopt this guidance in fiscal 2025and is in the process of evaluating the new requirements. As a result, the Company has not yet determined the impact this new ASU will have on its disclosures. ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses In November 2024, the FA

View Full Filing

View this 10-Q filing on SEC EDGAR